That did not happen despite both increasing pressure from members of Congress and a lawsuit brought by Sandoz Pharmaceuticals. The company is still waiting for the FDA to act on an application for approval of its growth hormone Omnitrope that they submitted in July 2003. The company's application relied on data produced for the innovator product, Pfi zer's Genotropin.
The FDA seems to have stepped back under increasing pressure from industry. However, the agency has continued to hold forums in which experts are helping to build the science needed to better assess the properties of biologics.
While that has helped defi ne what is needed to show equivalency, it has also made it clear that the agency will need to judge generic agents on a case-by-case basis, said Shari Dermer, Ph.D., a former biotech scientist and organizer of a December follow-on biologics workshop cosponsored by the FDA and the New York Academy of Sciences.
But before that can happen, Congress will need to create the legal authority the FDA needs to base the approval of generic proteins on data collected during testing of branded products, she said.
Generic versions of more simple molecules, such as human growth hormone, may require relatively little additional proof to meet FDA's needs compared with some more complex biologics, but the standards for abbreviated approval of biologics in general are likely to be more stringent than what the agency requires for standard, more easily defi ned drugs, she said.
" Omnitrope is going to be a bellwether of what might happen in the U.S., " said Dermer.
-Joel B. Finkelstein
